2 weeks Ago By Defense World Staff
Shares of Incyte Co. ( NASDAQ:INCY – Get Free Report ) have received a consensus recommendation of “Hold” from the twenty-one analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation and nine have issued a buy recommendation on the company.
The average 1-year target price among brokers that have covered the stock in the last year is $77.16. A number of analysts have recently commented on the company.
Morgan Stanley lifted their price target on Incyte from $64.00 to $69.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th.
Citigroup boosted their target price on shares of Incyte from $92.00 to $97.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th.
Oppenheimer boosted their price objective on shares of Incyte from $81.00 to $82.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th.
StockNews.com lowered Incyte from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Finally, BMO Capital Markets reissued an “underperform” rating and issued a $52.
00 price target (up previously from $48.00) on shares of Incyte in a research note on Wednesday, October 30th. Read Our Latest Stock Analysis on Incyte Insider Buying and Selling at Incyte Institutional Trading of Incyte Several institutional investors have recently made changes to their positions in the company.
MFA Wealth Advisors LLC bought a new stake in Incyte in the 2nd quarter worth about $26,000. Brooklyn Investment Group bought a new stake in Incyte during the third quarter worth $30,000. Point72 Asia Singapore Pte.
Ltd. bought a new stake in Incyte during the third quarter worth $33,000. Innealta Capital LLC purchased a new position in Incyte in the second quarter worth $32,000.
Finally, Cromwell Holdings LLC grew its stake in Incyte by 101.1% in the 3rd quarter. Cromwell Holdings LLC now owns 563 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 283 shares during the period.
Institutional investors own 96.97% of the company’s stock. Incyte Price Performance Incyte stock opened at $71.
72 on Friday. Incyte has a 52 week low of $50.35 and a 52 week high of $83.
95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.
82 and a current ratio of 1.87. The stock has a fifty day moving average of $69.
90 and a 200-day moving average of $64.47. The stock has a market capitalization of $13.
82 billion, a P/E ratio of 512.32, a price-to-earnings-growth ratio of 8.12 and a beta of 0.
71. Incyte ( NASDAQ:INCY – Get Free Report ) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.
07 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.12).
The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.08 billion.
Incyte had a net margin of 0.80% and a negative return on equity of 0.63%.
The company’s revenue for the quarter was up 23.8% compared to the same quarter last year. During the same period last year, the firm posted $0.
91 earnings per share. On average, sell-side analysts expect that Incyte will post 0.4 earnings per share for the current fiscal year.
About Incyte ( Get Free Report Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Featured Stories Five stocks we like better than Incyte The How and Why of Investing in Gold Stocks Vertiv’s Cool Tech Makes Its Stock Red-Hot Canadian Penny Stocks: Can They Make You Rich? MarketBeat Week in Review – 11/18 – 11/22 Trading Halts Explained 2 Finance Stocks With Competitive Advantages You Can’t Ignore Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.
com's FREE daily email newsletter ..
